beta

CHRS

Coherus BioSciences, Inc.

Chrs

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Market Cap: 1.39 Billion

Primary Exchange: NASDAQ

Website: http://www.coherus.com

Shares Outstanding: 70.1 Million

Float: 63.8 Million

Dividend: (%)

Beta: 1.08915749800123

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 1264 trading days

From: 2015-07-22 To: 2020-01-16

Lowest Point:

BIIB Is For Buy-O-Gen

via: SeekingAlpha at 2019-06-12 06:30:36:000

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...

BIIB Is For Buy-O-Gen

via: SeekingAlpha at 2019-06-12 06:30:36:000

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud